Elron Ventures Ltd · TASE:ELRN
Elron Ventures — Elron Electronic Industries — Investor Presentation (March 2016)
44 slides from Elron Ventures's investor presentation, Mar 15, 2016
Slide 1: Elron - Investor Presentation
DISCOVER. INNOVATION ELRON - INVESTOR PRESENTATION March 2016
Slide 2: Disclaimer and forward-looking statements
This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the features or content presented
Slide 3: Forward-looking information notice
This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 4: Discover. Elron
DISCOVER. ELRON
Slide 5: Operational holding company in the VC space
OPERATIONAL HOLDING COMPANY IN THE VC SPACE WE SPECIALIZE IN MEDICAL DEVICE TECHNOLOGIES WITH SIGNIFICANT EXIT POTENTIAL +WE HAVE 50 YEARS EXPERIENCE IDENTIFYING OPPORTUNITIES, BUILDING TECHNOLOGY LEADERS, AND EXITING HOLDINGS +WE INVEST PRIMARILY IN EARLY STAGE COMPANIES +WE RELY ON A PROVEN STRATE
Slide 6: Performance
PERFORMANCE CUMULATIVE PROFIT: $1.681\ DIVIDENDS: $225! Exit Proceeds, aftertax (sm)* 2010 2011 2012 2013 2014 2018 Gain (sm) em 85.5 663 I 44 ae 25 s4 a | Z 2010 2011 2012 2013 2014 2015 Investments (sm)* lliii 2010 2011 2012 2013 2014 2018, Liquid Resources at Year End (sm) 937 iiscll Eiasill 2010
Slide 7: Holdings in companies
Holdings in companies 1 Book value at Dec. 31, 2015 ($m) Amount invested ($m) Associates and consolidated companies: Pocared (58%) 15.6 53.4 BrainsGate (30%) 0.4 24.5 PLYmedia (25%) - 2.5 Others 13.0 22.8 Companies presented at fair value: Notal Vision (21%) 15.7 10.1 Others 4.6 18.6 Total Holdings
Slide 8: Discover. BrainsGate
DISCOVER. BRAINSGATE
Slide 9: Our investment: $25M, our holding: 30%
OUR INVESTMENT: $25M OUR HOLDING: 30%
Slide 10: Stroke statistics
Sources: American Heart Association: Heart Disease and Stroke Statistics Report - 2015; BrainsGate website: http://brainsgate.com/eng/page.php?id=3&instance_id=9.
Slide 11: Stroke disability and lifetime cost
Sources: American Heart Association: Heart Disease and Stroke Statistics Report - 2010, 2015; CDC website: http://www.cdc.gov/stroke/facts.htm. mRS Average Lifetime Cost Per Stroke Patient Sources: Samsa et al, Performing Cost-Effectiveness Analysis by Integrating Randomized Trial Data with a Compre
Slide 12: Thrombolysis treatment trends
Source: American Heart Association: Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals, Schwamm, Circ Cardiovasc Qual Outcomes. 2013;6:543-549. 12
Slide 13: Limitations of current stroke treatment
Sources: Adams HP, et al (2003) Stroke 34 , 1056-83; del Zoppo GJ, et al (2009) Stroke 40 , 2945-48.
Slide 14: Thrombectomy trial studies
Sources: Broderick JP, et al (2013) New England Journal of Medicine 368 (10), 893-903; Ciccone A, et al (2013) New England Journal of Medicine 368 (10), 904-13; Kidwell CS, et al (2013) New England Journal of Medicine 368 (10), 914-23; Berkhemer OA, et al (2015) New England Journal of Medicine 372 (
Slide 15: BrainsGate: alternate therapy expanding treatment window to 24 hours
BRAINSGATE: ALTERNATE THERAPY THAT EXPANDS THE TREATMENT WINDOW TO 24 HOURS ELECTRODE: 24-HOUR TREATMENT ‘WINDOW + Electrical stimulation of the SPG (a nerve center behind the nasal cavity) using a miniature electrode + The electrode’s activation induces dilation of cerebral blood vessels, and augme
Slide 16: BrainsGate ISS system
BrainsGate’s ISS is an investigational device, not approved for marketing. GuideView SPG (sphenopalatine ganglion) = supplies parasympathetic innervation to the anterior cerebral circulation and some of the posterior circulation Transmitter = emits RF waves which energize the implant Implant = deliv
Slide 17: Forward-looking information notice
This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 18: Discover. Pocared
DISCOVER. POCARED
Slide 19: Our investment: $53M, our holding: 58%
OUR INVESTMENT: $53M OUR HOLDING: 58%
Slide 20: Limitations of traditional microbiology testing
Over-/mis-prescribing antibiotics while awaiting lab results (promotes antibiotic resistance) Costly lab tests Since the 19 th century, microbiology testing has been done by culturing bacteria in petri dishes Expensive: Requires reagents and skilled lab technicians Manual: Prone to human error, limi
Slide 21: Antibiotic resistance timeline
1940 1959 1968 1962 1979 1988 1998 1987 1996 2001 2004 2011 Resistance identified Antibiotic introduced Sources: CDC, Antibiotic Resistance Threats in the United States, 2013; “FDA’s Take on the Executive Order and National Strategy to Combat Antibiotic-Resistant Bacteria”, posted on September 18, 2
Slide 22: Microbiology lab: last to implement full automation
THE MICROBIOLOGY LAB: THE LAST LAB TO IMPLEMENT FULL AUTOMATION © FEWER SKILLED WORKERS. HIGHER THROUGHPUT © GREATER EFFICIENCY f The average age of the lab workforce inthe | Testing volumes are increasing 10-25% per Economic pressures drive the need to USS. is about 50, and increasing year, due to
Slide 23: Pocared P-1000 Analyzer and Sample Processor
Sample Processor User interface The P-1000 Analyzer is investigational in the U.S., and CE-marked in the EU. The Sample Processor is exempt from regulatory approvals.
Slide 24: Forward-looking information notice
This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 25: Pocared data
Source: Pocared data. This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 26: Discover. Notal Vision
DISCOVER. NOTAL VISION
Slide 27: Our investment: $10M, our holding: 21%
OUR INVESTMENT: $10M OUR HOLDING: 21%
Slide 28: AMD destroys central vision
AMD destroys sharp, central vision, necessary for common tasks such as facial recognition, driving, reading, & watching television Sources: Brown DM, et al (2006). New England Journal of Medicine 355 , 1432-44; Slakter JS & Stur M (2005). S urvey of Ophthalmology 50 , 263-73; Gehrs KM, et al (2006).
Slide 29: Predicting wet AMD onset and monitoring
It is not possible to predict who will develop wet AMD, and if so, when Dry AMD patients are monitored once or twice a year, in routine check-ups at the eye doctor Wet AMD can be treated , but due to late diagnosis, 64% of eyes end with dysfunctional vision even after treatment Sources: Wittenborn J
Slide 30: ForeseeHome: saving the patient's vision
FORESEEHOME: SAVING THE PATIENT'S VISION BEFORE IT’S TOO LATE MORETHAN 3,500,000 TESTS TO DATE 8 5 8 FDA CLEARED CE MARKED CLINICALLY PROVEN ESTABLISHED REIMBURSEMENT ADOPTED INTHE AAOS's CLINICAL GUIDELINES eS PROVEN PREVENTION OF VISION Loss AREDS2: Notal Vision conducted a trial in collaboration
Slide 31: Forward-looking information notice
This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 32: Discover. CartiHeal
DISCOVER. CARTIHEAL
Slide 33: Our investment: $12M, our holding: 35%
OUR INVESTMENT: $12M OUR HOLDING: 35%
Slide 34: Cartilage lacks spontaneous healing potential
Cartilage does not possess spontaneous healing potential There are no treatments that halt the progression of osteoarthritis (OA) Sources: CDC website: http://www.cdc.gov/arthritis/basics/osteoarthritis.htm, http://www.cdc.gov/nchs/fastats/inpatient-surgery.htm; Losina E, et al (2015) Arthritis Care
Slide 35: Agili-C results post-op
12 weeks post-op 6 weeks post-op 3 weeks post-op The Agili-C is investigational in the U.S., and CE-marked in the EU.
Slide 36: Forward-looking information notice
This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 37: Discover. Coramaze
DISCOVER. CORAMAZE
Slide 38: Our investment: €1.75M, our holding: 28%
OUR INVESTMENT: €1.75M OUR HOLDING: 28%* * 28% after the funding round will be completed; currently 17%.
Slide 39: Burden of valvular heart disease
Sources: Nkomo VT, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368: 1005 - 1011; coramaze website: http://www.coramaze.com.
Slide 40: Coramaze mitral valve system
REPOSITIONABLE, DOESN’T INJURE ADJACENT TISSUE PRESERVES NATURAL LEAFLETS, RESTORES THEIR FUNCTIONALITY A SAFE, SIMPLE, AND QUICK IMPLANTATION METHOD ATRAUMATIC ANCHORING IN THE LEFT ATRIUM SPACER THAT ENHANCES LEAFLET COAPTATION PERCUTANEOUS TRANSFEMORAL IMPLANTATION ê ê ê Coramaze’s system is an i
Slide 41: Mitral valve acquisitions by large medtech
ACQUIRER TARGET DEAL SIZE DEVICE STAGE Edwards Lifesciences CardiAQ Valve Technologies up to $400m ($350m upfront + milestone) mitral valve replacement clinical development Abbott Tendyne up to $250m ($225m upfront + milestone) mitral valve replacement clinical development Abbott Cephea Valve Techno
Slide 42: Cyber investment with Rafael
Our 1 st investment with Rafael (one of Israel’s largest defense companies) in the cyber space, in a company that designed a spear phishing mitigation solution for enterprises The company closed an $11m financing from Carmel Ventures and RDC (our subsidiary jointly held with Rafael) Secured contract
Slide 43: Forward-looking information notice
This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 44: Elron. Opportunity - Thank you
ELRON. OPPORTUNITY Thank you.
Elron Electronic Industries — Investor Presentation (March 2016) on 6ix